Paroxysmal Supraventricular Tachycardia
14
3
3
8
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
14.3%
2 terminated out of 14 trials
80.0%
-6.5% vs benchmark
43%
6 trials in Phase 3/4
38%
3 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (14)
Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia
The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)
A Multicenter Study of Pulsed Field Ablation for Paroxysmal Supraventricular Tachycardia
Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia
Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302
Outcomes of PFA Vs. RFA for Patients with PSVT: a Retrospective and Propensity Score Matching Study
MCG for Localization of Tachyarrhythmia's Origin
Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).
Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303
Pulsed Field Ablation for Paroxysmal Supraventricular Tachycardia（PSVT）
Zero-fluoroscopy Approach Versus Fluoroscopic Approach for the Ablation of Paroxysmal Supraventricular Tachycardia
Radiofrequency Ablation of Paroxysmal Supraventricular Tachycardia Using a Novel Catheter Equipped With Mini Electrodes
Study on Left Atrial Function of Paroxysmal Supraventricular Tachycardia After Radiofrequency Ablation
Oral Verapamil in Acute Paroxysmal Supra Ventricular Tachycardia(PSVT) Recurrence Control